Traditional Chinese medicine composition for treating anemia after tumor chemotherapy

Abstract

The invention discloses a traditional Chinese medicine composition for treating anemia after tumor chemotherapy. According to traditional Chinese medicine, middle and advanced tumors are non-cured after long-time treatment, excessive in pathogen and latent in pathogenic toxin, consumes yin and yang of qi and blood to form syndrome of qi-blood deficiency, and causes anemia clinically; further, chemotherapeutic medicine serves as both a main pathogen eliminating therapy to play the therapeutical effect of counteracting one toxin with another and exogenous medicine toxin to cause malfunction of internal organs including liver, spleen, kidney and the like so as to cause damage to massive hemocyte. According to the invention, the following traditional Chinese medicines silverweed cinquefoil root, thatch screwpine fruit, conic gymnadenia tuber, henry woodbetony root, rabdosia amethystoides, pigeonpea, gurgeon stopper, eclipta and flatstem milkvetch seed are selected to be decocted with water to form decoction, and the decoction is remarkable in curative effect through clinic trials.

Description

technical field [0001] The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for treating anemia after tumor chemotherapy. Background technique [0002] More than 50% of tumor patients will develop anemia throughout the course of the disease. Anemia not only has many accompanying clinical symptoms, but also affects the process of radiotherapy and chemotherapy and the quality of life of patients. The average survival period of cancer patients with anemia can be shortened by 20% to 43%. At present, recombinant human erythropoietin (rHuEPO) has a certain effect on the treatment of patients with tumor anemia, but about 40% to 60% of patients with tumor anemia are ineffective for rHuEPO treatment, and with the increase of the dose of rHuEPO, not only the treatment cost of patients increases, It can also lead to increased incidence of side effects of rHuEPO such as hypertension and thrombosis. Therefore, n...

AI Technical Summary

Problems solved by technology

At present, recombinant human erythropoietin (rHuEPO) has a certain effect on the treatment of patients with tumor anemia, but about 40% to 60% of patients with tumor anemia are ineffective for rHuEPO treatment, and with the increase of the dose of rHuEPO, not only the treatment cost of patients increases, It can also lead to increased incidence of side effects of rHuEPO such as high blood pressure and thrombosis. Therefore, new drugs have become a new demand for clinical treatment of anemia after cancer chemotherapy